Update shared on10 Sep 2025
Fair value Decreased 15%Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50.
What's in the News
- Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.
- EluPro is the first and only FDA-cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices (CIEDs) and neurostimulators, featuring a natural biologic scaffold and antibiotic delivery.
- A new study published in the Journal of Functional Biomaterials showed EluPro's biomatrix controls inflammation, supports vascularization, and promotes wound healing, potentially reducing risk of pocket infection.
- Elutia faces risks involving commercialization and market acceptance of EluPro, ongoing product liability litigation, pricing pressures, supplier dependencies, and regulatory challenges.
Valuation Changes
Summary of Valuation Changes for Elutia
- The Consensus Analyst Price Target has significantly fallen from $6.50 to $5.50.
- The Future P/E for Elutia has significantly risen from 24.41x to 44.81x.
- The Consensus Revenue Growth forecasts for Elutia has significantly fallen from 63.7% per annum to 32.2% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.